Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$57.92MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean E. Brynjelsen
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 44
- Beta
- 0.83
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 17.21
Financials
Revenue
$57.92M+11485.0%Net Income
$35.25MEBITDA
$24.76MFree Cash Flow
$35.23MEPS (diluted)
$1.06Shares Outstanding (diluted)
33.26M+912.6%Operating Expenses
$21.29MCash & Debt
$55.63MReturn of Capital
$0.00Revenue by Segment (annual)
$79.95MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $79.95M | $-4.60M | $-0.17 |
| 2024 | $39.01M | $-3.82M | $-0.15 |
| 2023 | $31.64M | $-936.0K | $-0.04 |
| 2022 | $21.25M | $-9.02M | $-0.36 |
| 2021 | $21.83M | $-1.96M | $-0.08 |
| 2020 | $39.0K | $-27.97M | $-1.33 |
| 2019 | $959.0K | $-18.32M | $-1.02 |
| 2018 | $0.00 | $-12.74M | $-1.99 |
| 2017 | $0.00 | $-7.16M | $-0.41 |
Valuation
ETONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (18)
- Newszacks.com·3d ago·Positive
Earnings Estimates Moving Higher for Eton Pharmaceuticals (ETON): Time to Buy? Eton Pharmaceuticals, Inc. (ETON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Eton Pharmaceuticals: The Commercial Model Is Finally Scaling Eton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a 49% adjusted EBITDA margin; 2026 revenue guidance increased to more than $175 million. LIBERVANT and ASN-001 are the main growth drivers, with potential launches in 2027 and 2028, respectively.
View source ↗ - Newszacks.com·16d ago·Neutral
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Eton Pharmaceuticals Q3 Earnings Call Highlights Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product portfolio.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Neutral
Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.07 per share a year ago.
View source ↗ - Newszacks.com·20d ago·Positive
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect? Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
… 2026 Financial Results on Thursday, November 5, 2026 DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
…sing Agreement for LIBERVANT® (diazepam) Buccal Film DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today…
View source ↗ - Newszacks.com·46d ago·Neutral
ETON Stock Surges 108% in Six Months: Here's What You Need to Know Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO® (miltefosine) capsules.
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
…Participate at 2026 Wells Fargo Healthcare Conference DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.
View source ↗ - Newsfool.com·100d ago·Negative
Why Eton Pharmaceuticals Is Top of the Class Today Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.
View source ↗ - Newsseekingalpha.com·100d ago·Negative
…arnings Like These Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·101d ago·Negative
Eton Pharmaceuticals Q2 Earnings Call Highlights Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.
View source ↗ - Newszacks.com·101d ago·Neutral
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2026.
View source ↗
Earnings
Thu, Mar 18(in 4 months)
Consensus estimate $0.39 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.50 vs $0.31beat
- Thu, Aug 13$0.35 vs $0.19beat
- Thu, May 14$0.05 vs $0.10miss
- Thu, Mar 19$0.05 vs $0.12miss
- Thu, Nov 6$-0.07 vs $0.16miss
- Thu, Aug 7$-0.10 vs $-0.01miss
Estimates and results for ETON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ETON officers and directors.
- Bought
- —
- Sold
- $32.1m
0 trades
33 trades
- Erdogan-trinkaus Ipeksold
- Erdogan-trinkaus Ipeksold
- Casamento Charles Jsold
- Casamento Charles Jsold
- Casamento Charles Jsold
- Casamento Charles Jsold
- Casamento Charles Jsold
- Krempa Davidsold
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Suozzihouse · NY03 · disclosed Dec 1, 2022 (51d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
